Diabetes Drug May Slow Parkinson’s Disease

There were also no noteworthy between-group differences in any of the secondary outcome measures, including the experiences of daily living subparts of the MDS-UPDRS, on-off patient diaries, timed motor tests, non–motor symptom scale, Mattis dementia rating scales, and quality-of-life scales.

“Whether exenatide acts as a novel symptomatic agent or has neuroprotective effects on the underlying Parkinson’s disease pathology remains unclear, but Athauda and colleagues’ study opens up a new therapeutic avenue in treatment of Parkinson’s disease,” Dr Poewe and Dr Seppi conclude.